[{"StockholdersEquityConverted_0_Q3_USD":-738841000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-364039000.0,"CommonStockSharesOutstanding_0_Q3_shares":147087891.0,"StockholdersEquity_0_Q3_USD":-743397000.0,"EarningsPerShareBasic_1_Q3_USD":-1.06,"EarningsPerShareBasic_3_Q3_USD":-2.88,"RevenuesConverted_1_Q3_USD":2344000.0,"RevenuesConverted_3_Q3_USD":56830000.0,"Assets_0_Q3_USD":781524000.0,"CommonStockSharesConverted_0_Q3_shares":153279652.0,"NetIncomeLossConverted_1_Q3_USD":-155935000.0,"NetIncomeLossConverted_3_Q3_USD":-415362000.0,"Ticker":"BBIO","CIK":"1743881","name":"BRIDGEBIO PHARMA, INC.","OfficialName":"BridgeBio Pharma Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1594164456.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211104"}]